ESTRO PT 2018

• In design-phase: The PC05 neoadjuvant protocol (preoperatively) for patients with resectable and marginally resectable cancers. Randomization between: – 59.40CGE to gross disease – 50.40CGE to regional nodes with a gross disease boost to 59.40CGE • Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers. • Lee RY, Nichols RC Jr, Huh SN, Ho MW, Li Z, Zaiden R, Awad ZT, Ahmed B, Hoppe BS. • J Gastrointest Oncol. 2013 Dec;4(4):374-9. doi: 10.3978/j.issn.2078-6891.2013.043.